Joshua Bilenker - Loxo Oncology President CEO, Director
CEO
Dr. Joshua H. Bilenker, M.D. is President, Chief Executive Officer, Director of Loxo Oncology Inc. Since November 2013, Dr. Bilenker has served as President and Chief Executive Officer since June 2013 and as a member of our board of directors since June 2013. Since November 2013, Dr. Bilenker has served as an Operating Partner at Aisling Capital LLC, or Aisling Capital, a private equity firm, where he was a Partner from January 2012 to October 2013 and previously served as a Principal from October 2008 to December 2011 and an Associate from April 2006 to September 2008. Dr. Bilenker is on the board of directors of T2 Biosystems and Viewray Inc. He also serves on the nonprofit boards of BioEnterprise and The NCCN Foundation. From 2004 to 2006, Dr. Bilenker served as a Medical Officer at the FDA in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree in English from Princeton University. since 2013.
| Age | 45 |
| Tenure | 11 years |
| Phone | 203 653-3880 |
| Web | www.loxooncology.com |
Loxo Oncology Management Efficiency
Loxo Oncology's management efficiency ratios could be used to measure how well Loxo Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CEO Age | ||
| Thomas Cregan | Eastern Co | N/A | |
| David Shewmaker | Eastern Co | N/A | |
| Stephen King | Dave Busters Entertainment | 59 | |
| Tom Cregan | Eastern Co | N/A | |
| Mark Hernandez | Eastern Co | 56 | |
| David Sharp | Rocky Brands | 58 | |
| August Vlak | Eastern Co | 57 | |
| Eric Mettemeyer | Eastern Co | N/A | |
| Gaofei Wang | Weibo Corp | 45 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 |
Loxo Oncology Leadership Team
Elected by the shareholders, the Loxo Oncology's board of directors comprises two types of representatives: Loxo Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Loxo. The board's role is to monitor Loxo Oncology's management team and ensure that shareholders' interests are well served. Loxo Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Loxo Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jacob Naarden, VP of Corporate Devel. and Strategy | ||
| James Barrett, Independent Director | ||
| Timothy Mayleben, Independent Director | ||
| Jennifer Low, Chief Medical Officer | ||
| Joshua Bilenker, President CEO, Director | ||
| Avraham Naider, Independent Director | ||
| Lori Kunkel, Director | ||
| David Bonita, Independent Director | ||
| Jennifer Burstein, Vice President - Finance, Principal Financial Officer and Principal Accounting Officer | ||
| Keith Flaherty, Director | ||
| Steven Elms, Independent Director | ||
| Alan Fuhrman, Independent Director | ||
| Steven Harr, Independent Director | ||
| Sara Slifka, Sr. Director of Operations | ||
| Nisha Nanda, VP of Devel. Strategy |
Loxo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Loxo Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 | |||
| Profit Margin | (43.49) % | |||
| Operating Margin | (50.33) % | |||
| Current Valuation | 6.56 B | |||
| Shares Outstanding | 30.75 M | |||
| Shares Owned By Insiders | 3.70 % | |||
| Shares Owned By Institutions | 92.93 % | |||
| Number Of Shares Shorted | 1.03 M | |||
| Price To Earning | (20.33) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Loxo Stock
If you are still planning to invest in Loxo Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Loxo Oncology's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |